Low intravenous infusion rates of [U-13C]palmitate were used to measure systemic palmitate flux at rest (0.5 nmol . kg-1 . min-1) and during exercise (2 nmol . kg-1 . min-1) in healthy adults. The 13C enrichment of plasma palmitate was determined by gas chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS). Palmitate flux was also measured using palmitate radiotracers, which were infused simultaneously to serve as a reference method. Flux values obtained using the two different methods were virtually identical. Overnight postabsorptive palmitate flux was measured on four occasions in three individuals; the flux values were highly reproducible with a coefficient of variation of 11% and 12% for intra-day measurement, and 13% and 8% for inter-day measurement, for [1-(14)C]palmitate and [U-(13)C]palmitate, respectively. During exercise, palmitate turnover measured with [U-(13)C]palmitate and [3H]palmitate were well correlated (r = 0.91). Compared to conventional stable isotope approaches, (e.g., [1-(13)C]palmitate analyzed by GC/MS), [U-(13)C]palmitate reduces the tracer dose by two orders of magnitude when the samples are analyzed with GC/C/IRMS. Uniformly labeled [13C]palmitate is suitable for the measurement of free fatty acid flux in humans.
No takes yet. Share an insight, caveat, or question.
Guo et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: